Tag Archives: Corvus Pharmaceuticals Inc

Mizuho Securities Keeps a Buy Rating on Corvus Pharmaceuticals Inc (CRVS)

In a report released yesterday, Mara Goldstein from Mizuho Securities maintained a Buy rating on Corvus Pharmaceuticals Inc (CRVS – Research Report), with a price target of $7.00. The company’s shares closed last Monday at $3.66. According to TipRanks.com, Goldstein

Mizuho Securities Sticks to Its Buy Rating for Corvus Pharmaceuticals Inc (CRVS)

In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Corvus Pharmaceuticals Inc (CRVS – Research Report), with a price target of $7. The company’s shares closed last Monday at $4.15, close to its 52-week

Cowen & Co. Keeps Their Buy Rating on Corvus Pharmaceuticals Inc (CRVS)

Cowen & Co. analyst Boris Peaker maintained a Buy rating on Corvus Pharmaceuticals Inc (NASDAQ: CRVS) today. The company’s shares closed yesterday at $8.20. According to TipRanks.com, Peaker is a 4-star analyst with an average return of 8.3% and a

Cowen & Co. Thinks Corvus Pharmaceuticals Inc’s Stock is Going to Recover

In a report released yesterday, Boris Peaker from Cowen & Co. maintained a Buy rating on Corvus Pharmaceuticals Inc (NASDAQ: CRVS). The company’s shares opened today at $7.76, close to its 52-week low of $7.42. According to TipRanks.com, Peaker is

Corvus Pharmaceuticals Inc Receives a Buy from BTIG

BTIG analyst Dane Leone reiterated a Buy rating on Corvus Pharmaceuticals Inc (NASDAQ: CRVS) yesterday and set a price target of $26. The company’s shares closed yesterday at $12.32. Leone observed: “Corvus provided an update on the CPI-444 program at

Analysts Are Bullish on These Healthcare Stocks: CRVS, GLYC

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Corvus Pharmaceuticals Inc (NASDAQ: CRVS) and GlycoMimetics (NASDAQ: GLYC) with bullish sentiments. Corvus Pharmaceuticals Inc (NASDAQ: CRVS) In a report released yesterday,